Endocrine Abstracts

Introduction: National audits suggest significant variation in experience of individual surgeons performing adrenalectomies. A 2016 cross specialty consensus statement recommended that adrenal surgeons perform a minimum of six adrenalectomies per year given improved outcomes with higher volume surgeons. Patients in the Scottish Highlands requiring adrenalectomy are referred to a single Consultant Urologist with a specialist interest in retroperitoneal surgery based in Raigmore...

Introduction: Cinacalcet is an allosteric modulator of the calcium sensing receptor which lowers parathyroid hormone (PTH) secretion. However, it is expensive and there is limited evidence of benefit in reducing complications of primary hyperparathyroidism (PHPT). In 2019 the National Institute for Health and Care Excellence (NICE) guidelines suggested that cinacalcet could be considered in individuals with PHPT if surgery has been unsuccessful or is unsuitable and if adjCa<su...

Background: Given the technically challenging nature of adrenal venous sampling (AVS) there is a drive to centralise services to improve successful outcomes. This has potential implications for patients living in remote and rural areas.Methods: We retrospectively reviewed the case notes of 15 patients who underwent AVS in our hospital, for investigation of primary hyperaldosteronism between 2002 and 2015. We assessed the success rate of cannulation of th...

5α-Reductase 1 (5aR1) catalyses A-ring reduction of glucocorticoids and androgens, predominantly in liver and modulates steroid hormone action. We previously demonstrated transgenic disruption of 5aR1 predisposes mice to developing fatty liver. Here we tested whether 5aR1 disruption increases susceptibility to the development of liver injury, using the carbon tetrachloride induced liver fibrosis model.Male 5aR1−/− (KO) mice and wild-type...

Background & Aims: Observational studies implicate glucocorticoid excess, principally due to altered steroid metabolism in target tissues, in both the insulin resistance and liver fat accumulation that accompanies type 2 diabetes. To test the contribution of glucocorticoid signalling to metabolic dysfunction we blocked cortisol secretion (with metyrapone) and action (with the GR antagonist mifepristone) simultaneously in men with type 2 diabetes ± fatty liver.<p c...